By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing increasing competition in the human papillomavirus testing space and possible austerity measures by the US government, investment firm Macquarie downgraded Qiagen's shares and revised revenue and EPS estimates on Wednesday.

Macquarie also lowered the target price on Qiagen's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.